Thymosin α1 rescues cftr activity

Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein and is characterized by chronic lung inflammation. Romani

_et al_. show that the naturally occurring polypeptide thymosin α1 — clinically used as an immunotherapeutic agent — not only limited the inflammatory response when injected into a mouse

model of cystic fibrosis, but also rescued the activity of CFTR in these mice and in human bronchial epithelial cells from subjects carrying _CFTR_F508del (the most common mutation among

individuals with cystic fibrosis). REFERENCES * Romani, L. et al. Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis. _Nat. Med._

http://dx.doi.org/10.1038/nm.4305 (2017) Download references Authors * Sarah Crunkhorn View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Crunkhorn, S. Thymosin α1 rescues CFTR activity. _Nat Rev Drug Discov_ 16, 386 (2017).

https://doi.org/10.1038/nrd.2017.99 Download citation * Published: 31 May 2017 * Issue Date: June 2017 * DOI: https://doi.org/10.1038/nrd.2017.99 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative